Illumina, Inc. (ILMN) on Decifer

Why it ranks here

• Sales are growing about 6% a year, faster than 24 in 100 companies we measure.
• It keeps about 21 cents of every sales dollar as cash, safer than 84 in 100 companies we measure.
• It earns about 12% a year on the money put into the business, better than 64 in 100 companies we measure.
• It costs about 52 times its yearly profit; the middle of its industry is 37. Cheaper than 27 in 100 companies we measure, against their own industries.

The current read

The evidence on ILMN lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Genomic Medicine & Precision Diagnostics: The collapsing cost of DNA/RNA sequencing and validation of genomic classifiers is moving clinical practice toward routine molecular diagnostics and companion testing.

Read the full ILMN research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.